An epigenomic approach to therapy for tamoxifen-resistant breast cancerQin Feng, Bert W. O’Malley, Zheng Zhang et al.|Cell Research|2014Cited by 188
FOXA1 overexpression mediates endocrine resistance by altering the ER transcriptome and IL-8 expression in ER-positive breast cancerXiaoyong Fu, Rachel Schiff, Carmine De Angelis et al.|Proceedings of the National Academy of Sciences|2016Cited by 185
Overcoming endocrine resistance due to reduced PTEN levels in estrogen receptor-positive breast cancer by co-targeting mammalian target of rapamycin, protein kinase B, or mitogen-activated protein kinase kinaseXiaoyong Fu, Rachel Schiff, Chad J. Creighton et al.|Breast Cancer Research|2014Cited by 70
The oral selective oestrogen receptor degrader (SERD) AZD9496 is comparable to fulvestrant in antagonising ER and circumventing endocrine resistanceAgostina Nardone, Rachel Schiff, Hazel M. Weir et al.|British Journal of Cancer|2018Cited by 65
Therapeutic potential of the dual EGFR/HER2 inhibitor AZD8931 in circumventing endocrine resistanceGladys Morrison, Rachel Schiff, Xiaoyong Fu et al.|Breast Cancer Research and Treatment|2014Cited by 61